An Open-label, Single-group Trial to Evaluate the Effect of Pirfenidone on the Pharmacokinetics of a Single Oral Dose of BI 1015550
Latest Information Update: 28 May 2025
At a glance
- Drugs Nerandomilast (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 21 May 2025 Planned End Date changed from 15 Aug 2025 to 27 Oct 2025.
- 21 May 2025 Planned primary completion date changed from 1 Aug 2025 to 20 Oct 2025.
- 21 May 2025 Planned initiation date changed from 30 Apr 2025 to 6 Jun 2025.